Also linked to Pancreatic & Thyroid Cancers.
Recently, the U.S. Food and Drug Administration (FDA) announced that it is investigating the link between serious heart failure and deaths associated with the diabetes drug Onglyza®(saxagliptin). A recent study published in the New England Journal of Medicine reported an increased rate of hospitalization for heart failures.
In April 2014, after reviewing the study results which involved over 16,000 clinical trial patients, the FDA advisory panel voted 14-1 to add information about the increased risk of heart failure to the Onglyza® label. Drugs like Onglyza® have already been associated with other serious injuries including pancreatic cancer and thyroid cancer.
If you or a loved one has been hospitalized for heart failure, or if a loved one has died from heart failure, after taking Onglyza®, please call us today. We are also taking cases involving pancreatic cancer and thyroid cancer in patients taking Onglyza®.